- Home
- PBYI vs INSI Comparison
PBYI vs INSI Comparison
Compare PBYI & INSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- INSI
- Stock Information
- Founded
- PBYI 2010
- INSI 1971
- Country
- PBYI United States
- INSI United States
- Employees
- PBYI N/A
- INSI N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- INSI Investment Managers
- Sector
- PBYI Health Care
- INSI Finance
- Exchange
- PBYI Nasdaq
- INSI Nasdaq
- Market Cap
- PBYI 153.2M
- INSI 192.7M
- IPO Year
- PBYI N/A
- INSI N/A
- Fundamental
- Price
- PBYI $3.09
- INSI $17.06
- Analyst Decision
- PBYI Strong Buy
- INSI
- Analyst Count
- PBYI 1
- INSI 0
- Target Price
- PBYI $7.00
- INSI N/A
- AVG Volume (30 Days)
- PBYI 754.5K
- INSI 22.0K
- Earning Date
- PBYI 02-27-2025
- INSI 01-01-0001
- Dividend Yield
- PBYI N/A
- INSI 4.90%
- EPS Growth
- PBYI 492.79
- INSI N/A
- EPS
- PBYI 0.47
- INSI N/A
- Revenue
- PBYI $243,569,000.00
- INSI N/A
- Revenue This Year
- PBYI N/A
- INSI N/A
- Revenue Next Year
- PBYI N/A
- INSI N/A
- P/E Ratio
- PBYI $6.63
- INSI N/A
- Revenue Growth
- PBYI 6.30
- INSI N/A
- 52 Week Low
- PBYI $2.23
- INSI $14.28
- 52 Week High
- PBYI $7.73
- INSI $16.40
- Technical
- Relative Strength Index (RSI)
- PBYI 49.17
- INSI 47.55
- Support Level
- PBYI $2.92
- INSI $16.96
- Resistance Level
- PBYI $4.06
- INSI $17.37
- Average True Range (ATR)
- PBYI 0.29
- INSI 0.27
- MACD
- PBYI 0.01
- INSI 0.02
- Stochastic Oscillator
- PBYI 27.07
- INSI 64.77
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About INSI Insight Select Income Fund
Insight Select Income Fund is a diversified closed-end, management investment company. The fund's investment objective is to seek a high rate of return, primarily from interest income and trading activity, from a portfolio principally consisting of debt securities. It offers various solutions such as risk management, liquidity management, and return generation among others.